Abstract
Cocaine use disorders include short-term and acute pathologies (e.g. overdose) and long-term and chronic disorders (e.g. intractable addiction and post-abstinence relapse). There is currently no available treatment that can effectively reduce morbidity and mortality associated with cocaine overdose or that can effectively prevent relapse in recovering addicts. One recently developed approach to treat these problems is the use of enzymes that rapidly break down the active cocaine molecule into inactive metabolites. In particular, rational design and site-directed mutagenesis transformed human serum recombinant butyrylcholinesterase (BChE) into a highly efficient cocaine hydrolase with drastically improved catalytic efficiency toward (−)-cocaine. A current drawback preventing the clinical application of this promising enzyme-based therapy is the lack of a cost-effective production strategy that is also flexible enough to rapidly scale-up in response to continuous improvements in enzyme design. Plant-based expression systems provide a unique solution as this platform is designed for fast scalability, low cost and the advantage of performing eukaryotic protein modifications such as glycosylation. A Plant-derived form of the Cocaine Super Hydrolase (A199S/F227A/S287G/A328W/Y332G) we designate PCocSH protects mice from cocaine overdose, counters the lethal effects of acute cocaine overdose, and prevents reinstatement of extinguished drug-seeking behavior in mice that underwent place conditioning with cocaine. These results demonstrate that the novel PCocSH enzyme may well serve as an effective therapeutic for cocaine use disorders in a clinical setting.
Original language | English |
---|---|
Article number | 109961 |
Journal | Progress in Neuro-Psychopharmacology and Biological Psychiatry |
Volume | 102 |
DOIs | |
State | Published - Aug 30 2020 |
Bibliographical note
Publisher Copyright:© 2020 Elsevier Inc.
Funding
Work was supported in part by the National Institute for Drug Abuse (NIDA), United States, Grant DP1 DA031340 awarded to the Mayo Clinic (SB) and subcontracted to Arizona State University (TSM); NIDA, United States, Grant DA11064 awarded to Arizona State University (JN); and a NIDA, United States, Grant UH2/UH3 DA041115 to University of Kentucky (C-GZ). TSM, KEL and JN also thankfully acknowledge support for the animal experiments from the School of Life Sciences, Arizona State University, United States. Work was supported in part by the National Institute for Drug Abuse (NIDA), United States , Grant DP1 DA031340 awarded to the Mayo Clinic (SB) and subcontracted to Arizona State University (TSM) ; NIDA, United States , Grant DA11064 awarded to Arizona State University (JN); and a NIDA, United States , Grant UH2/UH3 DA041115 to University of Kentucky (C-GZ) . TSM, KEL and JN also thankfully acknowledge support for the animal experiments from the School of Life Sciences, Arizona State University, United States .
Funders | Funder number |
---|---|
National Institute on Drug Abuse | R01DA011064, DP1 DA031340 |
Mayo Clinic Rochester | UH2/UH3 DA041115 |
School of Life Sciences, Arizona State University | |
University of Kentucky | |
Arizona State University |
Keywords
- Butyrylcholinesterase
- Cocaine addiction
- Cocaine hydrolase
- Cocaine overdose
- Plant biotechnology
- Plant-derived biologics
ASJC Scopus subject areas
- Pharmacology
- Biological Psychiatry